Hepatic Resection for Metastatic Pancreatic Cancer

NCT02892305 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2025-08-06

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the feasibility of an aggressive multimodal approach among patients with stage IV pancreatic cancer (PAC) with isolated, low-volume hepatic metastasis (LVHM). We will evaluate and describe the surgical and overall outcomes of an initial cohort of subjects who undergo pancreatectomy and hepatic resection/ablation for PAC with LVHM. The end of study results will be reviewed by the Hepatiobiliary Multidisciplinary Conference (HDMC) and Surgery Audit Committee (SAC) to determine the appropriateness of adding this treatment arm for patients with oligometastatic metastatic pancreatic cancer.

Conditions

  • Pancreatic Neoplasms
  • Neoplasm Metastasis
  • Liver Metastases

Interventions

PROCEDURE

Hepatic Resection or Ablation with Pancreaticoduodenectomy

Patients will undergo pancreaticoduodenectomy, or the Whipple procedure, which involves removal of the head of the pancreas, the duodenum, and a portion of the stomach, as well as the gallbladder and a portion of the bile duct. The patient will also undergo a Hepatectomy, the surgical resection or removal of all or part of the liver or Microwave Ablation (MWA) if determined by the surgeon to be the best course of care.

Sponsors & Collaborators

Principal Investigators

  • Sabino Zani, MD · Duke Health

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-18
Primary Completion
2023-05-17
Completion
2027-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02892305 on ClinicalTrials.gov